Fried Frank's representation of APP Pharmaceuticals in its acquisition by Fresenius SE is noted in <em>The New York Times</em> DealBook

Fried Frank's representation of APP Pharmaceuticals in its acquisition by Fresenius SE is noted in The New York Times DealBook

Fried Frank is mentioned for representing APP Pharmaceuticals in its acquisition by Fresenius SE, a German global healthcare group. Based on the $23.00 per share purchase price, the transaction values the fully diluted equity capital of APP at approximately US$3.7b; and with the CVR, if fully realized, at a value of US$4.6b.

news-detail.inc